(Total Views: 197)
Posted On: 01/08/2019 9:20:01 AM
Post# of 72443
Published Studies Confirm Cisplatin Remains Preferred Chemotherapy Component in Head and Neck Cancer Treatment; Innovation Pharmaceuticals on Target with Clinical Trials of Brilacidin for Preventing Severe Oral Mucositis
...In its goal to build a world-class clinical asset across the Brilacidin franchise, with the indication of severe OM a Company priority, Innovation Pharmaceuticals is preparing to seek scientific advice from the European Medicines Agency to round out European Union program requirements for Phase 3 clinical trials.
1 https://www.thelancet.com/journals/lancet/art...1/fulltext
2 https://www.thelancet.com/journals/lancet/art...X/fulltext
This fits for the potential of combined phase III trials both in the U.S. and Europe. Just need the partner to foot the bill and be non dilutive.
https://finance.yahoo.com/news/published-stud...00218.html
...In its goal to build a world-class clinical asset across the Brilacidin franchise, with the indication of severe OM a Company priority, Innovation Pharmaceuticals is preparing to seek scientific advice from the European Medicines Agency to round out European Union program requirements for Phase 3 clinical trials.
1 https://www.thelancet.com/journals/lancet/art...1/fulltext
2 https://www.thelancet.com/journals/lancet/art...X/fulltext
This fits for the potential of combined phase III trials both in the U.S. and Europe. Just need the partner to foot the bill and be non dilutive.
https://finance.yahoo.com/news/published-stud...00218.html
(3)
(0)Scroll down for more posts ▼
